Neurovance Completes Trial Recruitment For ADHD Drug

Neurovance, a clinical stage company focused on neuroscience, announced that it has completed enrollment for the human abuse liability (HAL) study for its drug Centanafadine SR for the treatment of adult patients with attention deficit hyperactivity disorder (ADHD).

Centanafadine is a norepinephrine- and dopamine-preferring triple reuptake inhibitor being developed for the treatment of adult patients with ADHD. Compared to the usual treatments for ADHD, Centanafadine is a novel non-stimulant medication for the disorder.

Through the HAL study, the company intends to demonstrate that the drug possesses the right ratio for the right patient, with decreased potential for abuse and diversion. The five-arm clinical HAL study is designed to investigate the abuse liability of the drug at two doses among qualified recreational stimulant users. Neurovance said it anticipates the trial to yield results during the fall this year.

Anthony McKinney, president and CEO of Neurovance, said, “This is the second major advancement in the development of centanafadine for adult ADHD. First, centanafadine’s efficacy was demonstrated in a pilot study presented at the Society of Biological Psychiatry Annual Scientific Meeting in May. Now this substantial HAL study will test centanafadine’s abuse profile against two powerful stimulants and placebo. If this registration-level study confirms the preclinical data, we can be more confident that centanafadine has the potential for less restrictive scheduling than the stimulants currently used to treat ADHD.”

ADHD affects approximately 10 million in the U.S. alone, with only one in ten receiving appropriate diagnosis and treatment. Adults with ADHD tend to be linked with serious psychiatric comorbidities such as anxiety, depression, and substance abuse.

Earlier this month the company announced the appointment of Brigitte Robertson as VP of Clinical Development at Neurovance. At the same time, the company announced the name change of its lead product from EB-1020 SR to Centanafadine SR as its non-proprietary label.